Brilliant violet 605

Manufactured by BD

Brilliant Violet 605 is a fluorescent dye used in flow cytometry and other fluorescence-based applications. It is designed to provide bright, photostable fluorescence when excited by a violet laser. The dye can be used to label a variety of biological samples, including cells, proteins, and other biomolecules.

Automatically generated - may contain errors

Lab products found in correlation

Ter119, by BioLegend (1 mentions) Rb6 8c5, by BioLegend (1 mentions) Brilliant violet 421, by BioLegend (1 mentions) Alexa fluor 700, by BioLegend (1 mentions) Alexa fluor 647 a 21245, by Thermo Fisher Scientific (1 mentions) Ra3 6b2, by BioLegend (1 mentions) Centricon plus 70 centrifugal filter, by Merck Group (1 mentions) Live dead near ir, by Thermo Fisher Scientific (1 mentions) Percp cy5, by BD (1 mentions) Mbl 3e7, by Thermo Fisher Scientific (1 mentions) Cytoflex flow cytometer, by Beckman Coulter (1 mentions)

Spelling variants of this product

IFNγ-Brilliant Violet 605 (3 citations) Brilliant Violet 605-CD4 (2 citations) Brilliant Violet 605-CD25 (2 citations) Brilliant Violet 605-conjugated anti-CD115 (clone T38–320 (2 citations) Brilliant Violet 605-CD11c (2 citations)

3 protocols using brilliant violet 605

Multicolor Flow Cytometry Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were purchased from BioLegend and used at a 1:400 dilution unless indicated otherwise: anti-CD45.1/Ly5.1 (APC-Cy7, A20), anti-CD45.2/Ly5.2 (Alexa Fluor 700, 104), anti-CD3e (FITC, 145-2C11), anti-CD11b/Mac-1 (1:1,600, FITC or PerCP-Cy5.5, M1/70), anti-Ly6C/Ly6G (1:1,600, FITC or PerCP-Cy5.5, RB6-8C5), anti-CD45R/B220 (FITC or APC, RA3-6B2), anti-Ter119 (FITC, Ter-119), anti-CD117/c-kit (Brilliant Violet 421 (1:600) or PE; BioLegend, or APC-H7, 2B8, (1:200) BD Bioscience), anti-Sca-1 (Pe-Cy7, E13-161.7), anti-CD48 (1:800, PerCP-Cy5.5, HM48-1), anti-CD150 (1:600, PE-Dazzle or 1:600 Brilliant Violet 605, TC15-12F12.2), anti-CD135/Flk2 (1:200, PE, A2F10.1, BD Pharmingen), anti-CD34 (1:30, Alexa Fluor 700 RAM34, eBioscience), anti-Ki67 (1:200, Alexa Fluor 647, 11F6), anti-CD201 (1:200, EPCR, PE anti-mouse, RCR16), anti-p-IRF3 (1:25, S396, D601M, rabbit monoclonal antibody 29047, Cell Signaling), goat anti-rabbit secondary (1:500, Alexa Fluor 647, A21245, Invitrogen), anti-γH2AX (1:100, Alexa Fluor 647 (Ser 139), 2F3) and anti-p65 (1:100, Alexa Fluor 488, p65, Santa Cruz Biotechnologies) antibodies.

Clapes T., Polyzou A., Prater P., S.a.g.a.r., Morales-Hernández A., Ferrarini M.G., Kehrer N., Lefkopoulos S., Bergo V., Hummel B., Obier N., Maticzka D., Bridgeman A., Herman J.S., Ilik I., Klaeylé L., Rehwinkel J., McKinney-Freeman S., Backofen R., Akhtar A., Cabezas-Wallscheid N., Sawarkar R., Rebollo R., Grün D, & Trompouki E. (2021). Chemotherapy-induced transposable elements activate MDA5 to enhance haematopoietic regeneration. Nature Cell Biology, 23(7), 704-717.

+ Open protocol

+ Expand

Generation of Tetramer Probes for Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

For tetramer probe generation, rPfCSP or S02-DsbC (S02 fused to the disulfide bond C protein) were first biotinylated and then respectively conjugated to the fluorophores FITC (fluorescein isothiocyanate) and BV605 (Brilliant™ Violet 605) (BD Biosciences). Biotinylation was performed using ligase Bir A (Avidity) at 30°C for 4 hours prior to buffer exchange with 1X PBS (pH 7.4) over a 30-kDa Centricon Plus-70 Centrifugal Filter (Millipore) to remove excess free biotin. Biotinylated rPfCSP and S02-DsbC were fluorescently labeled through sequential addition of streptavidin conjugated to FITC (SA-FITC) or BV605 (SA-BV605), respectively, in a 4:1 molar ratio.

Wang L.T., Pereira L.S., Flores-Garcia Y., O’Connor J., Flynn B.J., Schön A., Hurlburt N.K., Dillon M., Yang A.S., Fabra-García A., Idris A.H., Mayer B.T., Gerber M.W., Gottardo R., Mason R.D., Cavett N., Ballard R.B., Kisalu N.K., Molina-Cruz A., Nelson J., Vistein R., Barillas-Mury C., Amino R., Baker D., King N.P., Sauerwein R.W., Pancera M., Cockburn I.A., Zavala F., Francica J.R, & Seder R.A. (2020). A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity, 53(4), 733-744.e8.

+ Open protocol

+ Expand

Multiparametric flow cytometry analysis of SIV-specific T cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Multiparametric flow cytometry was performed on fresh, transduced PBMCs and on thawed PBMCs or disaggregated lymph node cells collected post-infusion. Cells were incubated with Live/Dead Near-IR (Invitrogen); Alexa Fluor 700 or Brilliant Violet 421 mouse anti-human CD3 (SP34-2), FITC or Brilliant Violet 650 mouse anti-human CD4 (M-T477), Brilliant Violet 510 or Brilliant Violet 786 mouse anti-human CD8 (RPA-T8), PerCP/Cy5.5 mouse anti-human CD95 (DX2), Brilliant Violet 605 mouse anti-human CD28 (28.2), PE-CF594 mouse anti-human CCR7 (150503), Brilliant Violet 510 mouse anti-human CD45RA (5H9), PE-Cy7 or Brilliant Violet 650 mouse anti-human CD20 (2H7) (BD Biosciences); Phycoerythrin (PE) or PE-Cyanine7 mouse anti-human CXCR5 (MU5UBEE) (eBiosciences); MBL (3E7) (Invitrogen) conjugated to Alexa Fluor 647. To detect SIV-specific CD8⁺ T cells, samples were incubated with PE-labeled GAG-CM9 (NIH Tetramer Core) at 37°C for 15 min prior to antibody staining. Samples were run on a CytoFLEX flow cytometer (Beckman) and analyzed with FlowJo software v10.7.1 (BD Life Sciences).

Pampusch M.S., Sevcik E.N., Quinn Z.E., Davey B.C., Berg J.M., Gorrell-Brown I., Abdelaal H.M., Rakasz E.G., Rendahl A, & Skinner P.J. (2023). Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Frontiers in Immunology, 14, 1101446.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!